Flow cytometric analysis of lung lymphocytes in lung transplant recipients.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Flow cytometric analysis of lung lymphocytes in lung transplant recipients.

Am J Respir Crit Care Med. 1996 Mar;153(3):1041-6. Unique Identifier : AIDSLINE MED/96185410
Crim C; Keller CA; Dunphy CH; Maluf HM; Ohar JA; Division of Pulmonology and Pulmonary Occupational Medicine,; Department of Internal Medicine, Saint Louis University Health; Sciences Center, Missouri 63110-0250, USA.

Abstract: Lung transplantation is an accepted therapeutic modality in end-stage lung disease. Presently, histologic examination of tissue by transbronchial biopsy remains as the definitive diagnostic procedure for determining rejection. To begin addressing the usefulness of flow cytometric analysis of bronchoalveolar lavage fluid (BALF) in acute lung rejection, we prospectively studied the expression of markers on lymphocytes from BALF samples removed from 10 lung and heart-lung transplant recipients and compared their pattern with that of BALF lymphs obtained from normal volunteers (Norm) and nonrejecting heart transplant recipients (HT) who were receiving similar immunosuppressive regimens. Compared with both Norm and HT subjects, CD4+ lymphocytes in the BALF of lung transplant recipients was significantly reduced. A greater percentage of the CD4+ lymphocytes in nonrejecting lung transplant subjects also expressed the interleukin-2 receptor, but only during the early post-transplant period, suggesting possible reactivity to persistent donor cells. However, the CD8+ lymphocytes were increased only in lung transplant recipients undergoing acute lung rejection. We conclude that the immunologic milieu is indeed altered in the transplanted lung. Further studies in lung transplant recipients are required to evaluate the role of flow cytometry in the early detection of acute lung rejection.

Keywords: Acute Disease Biological Markers/ANALYSIS Bronchoalveolar Lavage Fluid/CYTOLOGY/IMMUNOLOGY Case-Control Studies Comparative Study CD4 Lymphocyte Count CD4-Positive T-Lymphocytes/PATHOLOGY CD8-Positive T-Lymphocytes/PATHOLOGY *Flow Cytometry Gene Expression Regulation Graft Rejection/DIAGNOSIS/IMMUNOLOGY Heart-Lung Transplantation/IMMUNOLOGY/PATHOLOGY Human Immunosuppression Lung/IMMUNOLOGY/*PATHOLOGY Lung Transplantation/IMMUNOLOGY/*PATHOLOGY Lymphocyte Count Lymphocytes/IMMUNOLOGY/*PATHOLOGY Prospective Studies Receptors, Interleukin-2/ANALYSIS/GENETICS JOURNAL ARTICLE
960930
M9690937

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .